StreetInsider.com News Articles

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Mon, 24 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26969005.html

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Mon, 24 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26969005.html

Barclays flags an "attractive entry point" in this pharma stock

Thu, 20 Aug 2026 15:00:00 -0400

Barclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.

Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.

"Pain-fueled volatility overdone: <$30 Represents an Attractive Entry Point," analyst Jenna Davidner wrote, adding that the guidance cut "drove elevated volatility, which we think is largely overdone."

The bank trimmed its price target to $48 from $56, reflecting lower revenue and adjusted EBITDA estimates driven mainly by pricing dynamics for Nucynta. Shares are currently priced at around $27.40, with the stock down around 4.6% on

Barclays flags an "attractive entry point" in this pharma stock

Thu, 20 Aug 2026 15:00:00 -0400

Barclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.

Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.

Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays

Wed, 19 Aug 2026 03:21:13 -0400

Barclays analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $48.00 (from $56.00) while maintaining a Overweight rating.

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: FULLER & THALER ASSET MANAGEMENT, INC.

Fri, 14 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26932923.html

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: FULLER & THALER ASSET MANAGEMENT, INC.

Fri, 14 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26932923.html

Collegium Pharma (COLL) 2700 contracts of August 39 calls trade

Thu, 13 Aug 2026 15:57:44 -0400

Collegium Pharma (NASDAQ: COLL) 30-day option implied volatility is at 49; compared to its 52-week of 33 to 76 with a focus on 2700 contracts of August 39 calls.

Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 12

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916506.html

Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 12

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916506.html

Collegium Pharmaceutical launches $50M accelerated share repurchase

Thu, 13 Aug 2026 07:30:37 -0400

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has entered into an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock, according to a company statement.

The ASR is part of a $150 million share repurchase program authorized by Collegium's board of directors in July 2025. Upon completion of the ASR, the company will have $100 million remaining under that program.

Under the terms of the agreement, Collegium will pay $50 million to Jefferies LLC and will receive an initial delivery of 1,556,420 shares, based on the $25.70 closing stock price of Collegium's common stock on August 12,

Collegium Announces $50 Million Accelerated Share Repurchase Program

Thu, 13 Aug 2026 07:30:00 -0400

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

“Collegium’s

Collegium Announces $50 Million Accelerated Share Repurchase Program

Thu, 13 Aug 2026 07:30:00 -0400

“Collegium’s

Collegium Pharmaceutical (COLL) PT Lowered to $43 at Piper Sandler

Fri, 07 Aug 2026 07:48:57 -0400

Piper Sandler analyst David Amsellem lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $43.00 (from $45.00) while maintaining a Neutral rating.

Collegium Pharma (COLL) Tops Q2 EPS by 20c; Offers Guidance

Thu, 06 Aug 2026 08:17:37 -0400

Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $199.87 million versus the consensus estimate of $201.41 million.

FY2026 Outlook-

Revenue between $825 million to $855 million versus the consensus $869.9 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

Form 10-Q COLLEGIUM PHARMACEUTICAL For: Jun 30

Thu, 06 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260806/26878888.html

Form 10-Q COLLEGIUM PHARMACEUTICAL For: Jun 30

Thu, 06 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260806/26878888.html

Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 06

Thu, 06 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26878877.html

Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 06

Thu, 06 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26878877.html

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Thu, 06 Aug 2026 07:30:00 -0400

– Completed Acquisition of AZSTARYS^®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook –

– Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year –

– Generated JORNAY PM^® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year –

– Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales –

– Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million –

– Updates Full-Year 2026 Financial Guidance –

– Conference Call Scheduled for Today at 8:00 a.m. ET –

STOUGHTON, Mass., Aug.